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In patients with a particular disease or health condition, stratified medicine seeks to identify those
who will have the most clinical benefit or least harm from a specific treatment. In this article, the
fourth in the PROGRESS series, the authors discuss why prognosis research should form a
cornerstone of stratified medicine, especially in regard to the identification of factors that predict
individual treatment response
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A woman with newly diagnosed breast cancer is deciding on a
course of therapy, guided by her physician. Evidence on the
average prognosis1 and effectiveness of therapeutic interventions
is available from studies of large groups of patients with breast
cancer in observational studies and randomised trials. But the
patient and doctor are faced with making a decision in an
individual case, where the prognosis and response to treatment
may deviate from average. One way to select the optimal
treatment is to consider a test that predicts treatment effect, such
as the human epidermal growth factor receptor 2 (HER-2)
status.2 The use of HER-2 status in breast cancer management
is an example of the translation of results from prognosis
research toward improved patient outcomes. The prognosis of
breast cancer patients is highly variable,1HER-2 was discovered
as a prognostic factor,3 which provided a specific target for an
intervention (trastuzumab), which was then evaluated in trials
which recruited women with HER-2 positive cancers (see fig
1⇓). After the success of these trials in improving clinical
outcome, trastuzumab is now given to the subgroup (stratum)
of women who are HER-2 positive, but not to those testing
negative;4 this type of approach has been termed stratified
medicine.
The aims of this fourth paper in our PROGRESS series (www.
progress-partnership.org) are to describe the rationale for
stratified medicine, and to explain why prognosis research is
pivotal for this purpose; from identifying priority areas for
stratification, to discovering candidate factors that may predict
treatment response, through to trials and health technology
assessment that examine the impact of stratified medicine
approaches in healthcare. We identify current challenges and
deficiencies in such research and make recommendations for
improvement with examples across a variety of disease areas.
What is stratified medicine?
Stratified medicine refers to the targetting of treatments
(including pharmacological and non-pharmacological
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interventions) according to the biological or risk characteristics
shared by subgroups of patients. Stratified medicine is regarded
as central to the progress of healthcare according to the leaders
of the National Institutes of Health, and the Food and Drug
Administration6 among others.7 In contrast with “all comer” or
“empirical” medicine, stratified medicine seeks to target therapy
and make the best decisions for groups of similar patients.8 9
One approach to stratifying the use of treatments is to consider
absolute risks. In the third article of our series10 we described
how prognostic models are used to estimate the absolute risk
of an outcome for an individual. Those people with the highest
absolute risk will derive the largest absolute benefit from a
treatment (that is, the greatest reduction in probability of the
outcome) when the treatment effect expressed in relative terms
is the same for all patients. This is illustrated in the upper panel
of fig 2⇓, where the relative treatment effect on mortality risk
is estimated as 0.75 for all patients but the reduction in absolute
probability of death is 5% for low risk patients and 15% for
high risk patients. In such situations treatments could be
restricted (or “personalised”) to those who will benefit the most.
Examples in common clinical practice include the decision to
give lipid lowering therapy to people above a certain threshold
of cardiovascular risk estimated from a prognostic model,11 the
use of bisphosphonates for women over the age of 50 considered
to have an increased risk of vertebral fractures, and the targeting
of primary care management of back pain.12
By contrast, clinicians may also stratify medicine because the
relative treatment effect is inconsistent across patients (fig 2,
lower panel⇓). In this situation, at least one individual patient
measure is associated with changes in the treatment effect. In
statistical terms there is an interaction between a patient-level
variable and the effect of treatment on the outcome, and in
biological terms there may be an underlying mechanism
explaining the interaction. In this situation, a stratified medicine
approach seeks to test patients for the presence of individual
factors that are considered predictive of an improved treatment
response (more benefit, less harm, or both), as in the
aforementioned test for positive HER-2 status in breast cancer
and the use of trastuzumab. Other examples in clinical use
include imatinib in patients with chronic myeloid leukaemia
targeted to those with the BCR-ABL mutation13 and gefitinib
used to treat pulmonary adenocarcinoma in patients with
epidermal growth factor receptor mutations.14
An example of identifying patients with greater risk of harms
include the antiretroviral drug abacavir,15 where HLA typing
helps identify patients at high risk of abacavir toxicity. Thus a
key part of stratified medicine research is to identify suitable
tests for predicting treatment response from specific
interventions.
The use of HER-2 status in breast cancer management illustrates
how tests of differential treatment response are often thought
of as binary factors: a biomarker is classed as positive or
negative, or laboratory values are deemed low or high. Such
dichotomisation facilitates clinical decision making and is used
in most examples described in this paper. However, many tests
have original values measured on an ordinal or a continuous
scale. Similarly if prognostic models10 are considered as tests,
they usually produce a continuous risk score for each individual;
the same applies to gene signatures or related indices derived
from high dimensional data. Statistically, there is more power
and less potential for bias if such tests are evaluated on their
original scale (see later) rather than being dichotomised by
means of a cut point10; categorisation may then be done after
analysis to aid clinical strategies. For example, Flynn et al
derived a prognostic model to identify patients with back pain
who would respond well to manipulation rather than to other
types of treatment such as exercise.16 Some trials randomising
patients to these treatments found that patients with positive
scores from the model had greater relative and absolute benefits
from manipulation than those with negative scores.17 18
Thus stratified medicine uses baseline information about a
patient’s likely response to treatment to tailor treatment
decisions. This is different from stepped19 or adaptive20 models
of care in which tailoring of treatment depends on the patient’s
actual response to previously offered treatment, with a sequence
of interventions (which may differ in intensity, duration, cost,
or complexity) being offered to those who have not responded
sufficiently. Our focus here, though, is on the initial stratification
of treatment based on the predicted (rather than actual) response
to treatment.
Why is prognosis research important for
stratified medicine?
Prognosis research is a fundamental component of stratified
medicine because it contributes evidence at multiple stages in
translation (see fig 1⇓ as an example). We now consider each
of these stages in turn.
Assessing priorities for stratified medicine
Targeting interventions at defined patient strata is likely to be
more important in some disease-treatment combinations than
in others, and prognosis research can help prioritise areas for
research. Several questions arise. First, is there clinically
important variation in prognosis across individuals?1 For
example, among people with symptomatic severe aortic stenosis,
one year survival is poor and valve replacement or
implementation is the default option. By contrast, among people
with aortic regurgitation, one year survival is better, and so tools
to help decide when and for which patients valve replacement
would yield the greatest benefit, and incur the least harm, would
be a substantial advance. Second, is the intervention in question
associated with a substantial risk of harm or cost? Third, for
drug interventions, is there robust evidence of important
individual variation in metabolism or pharmacological effect?
For example, it has been claimed that some individuals have
“clinical aspirin resistance” if they sustain a cardiovascular
event despite aspirin prophylaxis. However, because of the lack
of an optimal assay of platelet function and the paucity of high
quality epidemiological data, it is unclear to what extent this
observation reflects true pharmacological resistance to aspirin,
non-adherence to medication,21 the expected reduction but not
abolition of cardiovascular risk from aspirin treatment, or some
combination of these factors.
Discovery and candidate approaches to
developing new tests
Prognosis research is important to identify which factors to
study as potential predictors of differential treatment response,
which might lead to a new prototype test (left hand of
translational pathway in fig 1⇓). Prognostic factors, which were
discussed in paper 2 of our series,3 are characteristics associated
with a particular outcome even in the absence of specific
treatment. Prognostic factors with causal or mechanistically
relevant effects are also potential predictors of differential
treatment response. For example, among people with atrial
fibrillation, age influences both response to warfarin and risk
of stroke, and so is a both a prognostic factor3 and a factor that
predicts differential treatment response.
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However, most prognostic factors do not also predict differential
treatment response.22 That is, they identify groups of patients
with different absolute outcome risks, but not groups with
different relative risks for a particular treatment. Conversely, a
factor that predicts differential treatment response is not
necessarily a prognostic factor. That is, some factors (such as
those that influence the metabolism or elimination of a specific
drug) may influence the response to treatment (that is, they
modify relative risk) without affecting prognosis in the absence
of treatment (that is, they do not change absolute risk). For
example, the CYP2C9 and VKORC1 genotypes are associated
with differential warfarin response but do not influence the risk
of stroke in the absence of warfarin treatment.23
DNA based, genome-wide association studies (genomics) and
mRNA based gene expression profiling (transcriptomics) of
disease affected tissues are beginning to uncover new and, in
some cases, unanticipated disease mechanisms and factors that
potentially predict differential treatment response.
Evaluation in randomised trials
Once a factor potentially predicting differential treatment
response has been identified the next step is to evaluate it, ideally
as an a priori primary objective within a randomised trial of the
specific therapy in question. Figure 2⇓ illustrates such a
comparison of outcomes in treated and control groups, separately
among factor positive and factor negative individuals. However,
few individual trials are large enough to assess reliably whether
a factor is truly predictive of treatment response as a primary
objective, so evidence may often appear gradually, from
secondary analyses of existing randomised trials and then their
meta-analysis. This process was used for examining whether
tamoxifen treatment of breast cancer differed according to the
oestrogen receptor status of the breast cancer.24
Evaluations of factors that may predict differential treatment
response become more pressing when a drug fails in late stage
trials after substantial research investment; there is then intense
interest in moving from targeting all people to identifying those
specific patients who may benefit. For example, gefitinib in
advanced non-small cell lung cancer failed to show a survival
benefit among all patients, and this stimulated exploratory
analyses in relation to epidermal growth factor receptor status.14
Even in trials that do show a positive average effect of a drug,
there may still be some patients who hardly benefit from the
drug, and it is clearly important to identify this subgroup.25
However, it is notoriously difficult to identify genuine predictors
of differential treatment from single trials, as such investigations
are usually exploratory with high potential for type I and type
II errors (see later).
Assessment of tests as a health technology
Even seemingly robust evidence for the existence of a factor
that predicts differential treatment response does not guarantee
that it will be effective when used as a test in clinical practice
to inform therapeutic decisions. Consider the example of
pharmacogenetic testing to guide warfarin dosing. Here the
testing, not the drug, is the technology being evaluated. In a
high quality meta-analysis of nine observational studies (2775
patients),26 CYP2C9*2 and CYP2C9*3 alleles were associated
with a requirement for a lower warfarin dose and an increased
risk of bleeding. Despite this clear association, which is unlikely
to have arisen by chance, a systematic review of three
randomised controlled trials did not provide evidence in favour
of warfarin dosing based on genetic information in comparison
with standard clinical care with respect to bleeding rate or time
spent in the therapeutic range.27
Cost effectiveness evaluations
Decision analytic models are important for the evaluation of
the cost effectiveness of stratified therapeutic strategies.28-30
These models require valid estimates of prognosis under
different scenarios, based on treatment with and without
knowledge of the predictor of differential treatment response.
Such models are important for policy makers because they
evaluate strategies which are unlikely to be evaluated within
trials. For example, decision analysis comparing different
strategies for assessing HER-2 status to decide on treating breast
cancer with trastuzumab found that fluorescent in situ
hybridisation testing for all patients, with one year of adjuvant
treatment with trastuzumab for those who were positive, was
associated with the longest quality adjusted survival, with an
estimated cost per quality adjusted life year gained of €41 500
(£32 600, $51 200).31 32
Healthcare policy and delivery
Health services research is required to examine variations in
the uptake of using tests to predict differential treatment
response,33 the validity of these tests,34 and variations in
treatments based on test results. Prognosis research also
examines endpoints in relation to these variations, allowing, for
example, national estimates to be made of the number of
endpoints averted by current levels of testing.35
Once incorporated in clinical practice guidelines4 and usual
clinical care, tests that predict differential treatment response
may help define the disease and how it is characterised. This is
termed “back translation.” For example, in breast cancer, HER-2
and oestrogen receptor status are predictors of differential
treatment response, and so their measurement is now integral
to the definition of the disease upon diagnosis.
Premature implementation of stratified medicine approaches
into clinical practice may be harmful if people who might
otherwise benefit from treatment are denied access. For example,
carriage of a variant of the KIF6 gene was associated with a
higher risk of coronary heart disease events and a smaller
reduction in event rate from statin treatment in a genetic
substudy from a randomised trial.36 It would have been
premature to implement these findings; indeed, a later, larger
meta-analysis of case-control studies of myocardial infarction
casts doubt on the role of this variant in coronary heart disease
and prediction of statin response,37 arguing that statins should
be used according to existing guidelines without any genetic
testing
Recommendations for improving
prognosis research for stratifiedmedicine
Several methodological challenges and current research
deficiencies need to be addressed in this field. Currently we
lack a systematic framework for guiding research on stratified
medicine, and standards must be raised. Many of the
recommendations highlighted across the PROGRESS series
(see supplementary table on bmj.com) are relevant. For example,
integrated standards of design, analysis, and reporting should
be developed across the stages of discovery, replication, and
evaluation of factors that potentially predict differential
treatment response38-43 (recommendation 10 in supplementary
table). Here we highlight four key areas, with recommendations
for improvement.
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False negative findings (type II errors)
There are important problems with statistical analyses, which
should be addressed by having a statistical analysis plan in the
protocol and by a greater appreciation of the potential for type
I and II errors that may lead to inappropriate conclusions
(recommendation 13 in supplementary table).
Most randomised trials are not designed with the statistical
power to detect a factor truly predictive of differential treatment
effect, should it exist, and so may wrongly conclude that a
particular factor is not useful as a predictive test when actually
it is.44 45 To increase power and reduce the opportunity for false
negatives, we recommend thatmeta-analyses based on individual
participant data from multiple trials are facilitated
(recommendation 17).46 This approach was crucial in
establishing the role of oestrogen receptor status for the targeting
of tamoxifen treatment in breast cancer,24 and researchers can
support its greater use by initiating collaborative groups and
data sharing.46 Another cause of false negative findings is the
aforementioned dichotomisation of continuous factors that may
predict treatment response, which reduces power further.
Statistical methods are available to screen a large number of
continuous factors on their original scale and identify their
potential interactions with treatment.47 Identified interactions
should be interpreted as hypothesis generating and replication
sought in other studies, and meta-analyses. Results for all
interactions and subgroups considered should be clearly reported
regardless of their significance (recommendation 15), and
guidelines for such reporting need development.
False positive findings (type I errors)
Subgroup analyses can provide valuable, albeit predominately
exploratory information, about factors that potentially predict
treatment response if they are performed in accordance with
recommendations and guidelines38 48 (recommendation 13).
However, inappropriate subgroup analysis of trial data can give
spurious evidence for stratified medicine. Firstly, because of
the large number of potential factors to consider, appropriate
correction for multiple statistical testing is required to reduce
the risk of false positives arising by chance.45 49 Alternatively,
we recommend that such analyses should be recognised as
exploratory and require replication using new data from related
studies and in meta-analysis of individual participant data
(recommendations 17 and 9).
Secondly, the choice and handling of endpoints can influence
interpretation of evidence about whether a factor predicts
treatment response. For example, in a field synopsis of
pharmacogenetic studies, there was evidence of bias in which
positive findings were more likely when examining surrogate
markers of treatment effects rather than the more clinically
relevant endpoints such as a disease complication or death.50
Thirdly, arbitrary or “data dredging” categorisation of
continuous factors and continuous outcomes can easily bias
findings toward a significant result, particularly if analyses are
repeated for multiple cut-offs until a categorisation is found that
provides the most significant P value.51 Continuous factors
should rather be analysed on their continuous scale to avoid
this.
Fourthly, as Senn has argued, studies claiming to distinguish
responders (say 70% of people) and non-responders (30%) after
a single exposure to a drug are also consistent with an alternative
explanation that 100% of patients respond 70% of the time,
which would indicate the absence of differential response to
treatment.52
Fifthly, a meta-analysis of summary data from trials may also
give misleading positive results, and a meta-analysis of
individual participant data is preferred. For example, fig 3⇓
shows ameta-analysis of summary data from 10 trials suggesting
women experience a greater and clinically important reduction
in blood pressure from hypertension treatment than men. By
contrast, in a meta-analysis of individual participant data from
the same trials this apparent sex-treatment interaction was found
to be small and not clinically important.46 53 The discrepant
findings were caused by study level confounding when looking
at aggregated relationships across trials, rather than investigating
patient level relationships within trials using individual
participant data.
Away from trials, many consider molecular andmicroarray data
are the key to stratified medicine, but so far the high expectations
have not been met, and a more realistic view is important.3 The
large number of variables collected in a relatively small number
of patients results in severe methodological problems,3 and type
I errors are again a particular concern.
Analyses restricted to just individuals testing
positive for a factor, or just individuals
receiving treatment
Robust trial designs to identify factors that truly predict
differential treatment response should ideally involve the four
groups of patients illustrated in the lower panel of fig 2⇓ so that
the difference in treatment effect between patients who are
positive for the factor and those who are negative can be
estimated (recommendation 22). However, such a design is
often not carried out.
Increasingly, drug trials are being undertaken exclusively among
individuals who test positive for a potential (but unproved)
factor that predicts differential treatment response (upper panel
of fig 4⇓). For example, a randomised trial of heart rate lowering
drug ivabradine failed to show a benefit in primary outcome of
events among people with stable coronary disease, but subgroup
analysis suggested a benefit among those with higher heart
rates.3 The subsequent trial was confined to people with higher
heart rates.
Emerging trial designs even propose the integration of drug
evaluation with the discovery and evaluation of novel biomarker
signatures in real time.3-55 Such studies are sometimes referred
to as enrichment trials because, by selecting people in whom
the treatment effect is hypothesised to be large, they provide a
mechanism for reducing the sample size of a trial. This is only
a sensible approach as long as inferences are restricted to the
selected patients in the trial. In particular, such trials cannot
then compare outcomes between patients with positive and
negative factor values, and so cannot assess whether the relative
treatment effect (or differences in absolute risk) are indeed
smaller in individuals with negative values for the factor, let
alone the differences in absolute risk.
Of muchmore concern are observational analyses (either within
or outside the framework of a trial) confined to just those who
are treated, as then no comparison can be made with control
patients and thus the treatment effect cannot be estimated. In
this type of approach, to be able to conclude that a factor truly
predicts treatment response, one must assume that the factor
does not influence the outcome of interest in the absence of
treatment (lower panel of fig 4⇓). If the factor is associated with
outcome in both treated and untreated individuals, then it may
be a prognostic factor (as discussed in paper 2 of our series3)
but not predictive of treatment response. Thus, the approach is
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more correctly interpreted as an evaluation of a prognostic factor
among those who are treated, but this is often not recognised.
Biological reasoning and prioritisation of
funding areas
Statistical evidence of an interaction between a particular factor
and treatment response should ideally be explained by biological
reasoning and by understanding the mechanism by which
response is modified. For instance, for drug interventions,
clinicians and policy makers are more likely to believe that a
factor truly modifies treatment response if there is a well
reasoned biological mechanism in addition to statistical
significance. Indeed, stratifiedmedicine researchmay be entirely
motivated by such a biological mechanism in the first place,
and funders should prioritise stratified medicine investigations
that have such plausibility. “Biological mechanism” should be
interpreted in a broad sense here, since behavioural and
sociocultural factors may be of equal importance (and have
plausible mechanisms for their effects on health outcomes) to
biologically measured factors and pathways.
There should be rigorous evaluation of the impact of
“personalised medicine” approaches on health outcomes,
including comparisons of approaches based on targeting
intervention (with prognostic models or factors that predict
differential treatment response) and “all comer” approaches
(recommendation 23 in supplementary table). In certain
situations subgroups with weaker treatment effects on relative
risk may have the greater potential benefit in terms of absolute
risk. Uncertainty about treatment effects is usually greater in
low risk groups, and adequately powered prognosis research is
required.
Funders and policymakers should also recognise that a treatment
may benefit all patients even when there is a factor that predicts
treatment response. In this situation, patients testing negative
for the factor will still benefit from the treatment, and so
treatment policies should not automatically exclude such
patients.
Industry interest (drug, device, biomarker, information
technology) in prognosis research including tests for stratified
medicine (sometimes called “companion diagnostics”), drug
safety, outcomes research and real world evidence is growing.
Appropriate models of industry and publicly funded prognosis
research should be developed which allow unbiased inference.
(recommendation 24 in supplementary table).
Conclusions
In this article we have illustrated and described how prognosis
research contributes important evidence in discovering,
developing, evaluating, and implementing new approaches in
stratified medicine, especially in identifying factors that truly
predict differential treatment response. Such research faces
many challenges, and often current study designs and statistical
analyses are substandard. We have provided recommendations
with the aim of accelerating the potential of prognosis research
in this context, and these build on others presented throughout
our PROGRESS series to improve the care, treatment, and
clinical outcomes of individual patients.
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Summary points
The PROGRESS series (www.progress-partnership.org) sets out a framework of four interlinked prognosis research themes and provides
examples from several disease fields to show why evidence from prognosis research is crucial to inform all points in the translation of
biomedical and health related research into better patient outcomes. Recommendations are made in each of the four papers to improve
current research standards
What is prognosis research? Prognosis research seeks to understand and improve future outcomes in people with a given disease or
health condition. However, there is increasing evidence that prognosis research standards need to be improved
Why is prognosis research important? More people now live with disease and conditions that impair health than at any other time in
history; prognosis research provides crucial evidence for translating findings from the laboratory to humans, and from clinical research
to clinical practice
Stratified medicine involves tailoring therapeutic decisions for specific, often biologically distinct, individuals, the aim being to maximise
benefit and reduce harm from treatment, or to rescue a treatment that fails to show overall benefit in unselected patients but does benefit
specific patients
Stratified medicine can use absolute risks. When a treatment effect measured on a relative scale (such as relative risk) is the same for
all patients, those with the highest absolute risk will derive the largest absolute benefit from the treatment
When the relative treatment effect is inconsistent across patients, stratified medicine can use tests which measure factors (such as
biomarker levels or genotypes) that predict individual treatment response. However, the clinical use of such tests is currently small, and
rigorous evidence of impact is sometimes lacking, with flaws in study design, analysis, and reporting leading to potentially spurious
evidence either for or against a factor
Research to identify factors that truly predict treatment effect could be improved by:
Labelling exploratory analyses as exploratory, to minimise false positive findings
Increasing statistical power by designing trials with adequate sample sizes, facilitating collaborations across research groups and
meta-analyses of individual participant data from multiple trials, and by analysing continuous factors on their original scale
Estimating, for a truly binary factor, the difference in relative treatment effect between positive and negative groups within randomised
trials that include both factor positive and factor negative patients in both control and treatment groups
Considering biological or other mechanisms for modification of treatment response, either to motivate new research or to support
statistical evidence that a factor interacts with treatment
Prognosis research in general should play a more central role in stratified medicine research: from identifying conditions with clinically
important differences in absolute risk of outcome across patients, to identifying factors that predict individual treatment response, and
to examining the cost and impact of implementing stratified medicine approaches in practice
The other papers in the series are:
PROGRESS 1: BMJ 2013, doi:10.1136/bmj.e5595
PROGRESS 2: PLoS Med 2013, doi:10.1371.journal/pmed.1001380
PROGRESS 3: PLoS Med 2013, doi:10.1371.journal/pmed.1001381
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Figures
Fig 1 Example of stratified medicines research, with translation from discovery of human epidermal growth factor receptor
2 (HER-2) status as a prognostic factor for metastatic breast cancer5 to development of trastuzumab treatment and use in
clinical practice. Path element adapted from chart 7.1 in the Cooksey report (2006) (made available for use through the
Open Government License)
Fig 2 Estimated treatment effect in subgroups defined according to (upper panel) risk from a prognostic model and (lower
panel) a factor that predicts differential treatment response. The prevalence of positive factor and high risk is shown,
arbitrarily, as 20%. The dotted vertical line shows the overall treatment effect, the centre of each box shows the effect
estimate, and the horizontal lines show confidence intervals
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Fig 3 Example of spurious finding in meta-analysis of summary data refuted by meta-analysis of individual participant data:
whether antihypertensive treatment has a greater effect in women than men (reproduced with permission from Riley et
al46 53)
Fig 4Commonly used (but suboptimal) study designs in assessment of a factor that potentially predicts differential treatment
response
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